Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 11/20 | 0.71 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31095312 | 1.00 | CHUK (0.71) | CHUKLRRK2ROCK2ROCK1CDC42BPA | |
| SCHEMBL24136246 | 0.80 | CHUK (0.68) | CHUKLRRK2ROCK2ROCK1CDC42BPA | |
| SCHEMBL14421907 | 0.79 | CHUK (0.61) | CHUKLRRK2ROCK2ROCK1CDC42BPA | |
| SCHEMBL22280368 | 0.78 | CHUK (0.51) | CHUKLRRK2ROCK2ROCK1CDC42BPA | |
| SCHEMBL31022852 | 0.77 | CHUK (0.44) | CHUK | |
| SCHEMBL22280208 | 0.76 | MAP3K7 (0.47) | CHUKLRRK2ROCK2ROCK1CDC42BPA | |
| SCHEMBL20343974 | 0.76 | CHUK (0.65) | CHUKLRRK2IKBKB | |
| SCHEMBL22280088 | 0.76 | CHUK (0.47) | CHUKLRRK2ROCK2ROCK1CDC42BPA | |
| SCHEMBL18383137 | 0.76 | MAP3K7 (0.47) | CHUKLRRK2ROCK2ROCK1CDC42BPA | |
| SCHEMBL154683 | 0.75 | CHUK (0.61) | CHUKLRRK2ROCK2ROCK1CDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656249-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-12-03 | — | — | EP | disclosed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| WO-2024233605-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-110913855-B | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-3478687-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2024-03-20 | — | — | EP | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| CN-111527091-A | Oxy-fluoropiperidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2020-08-11 | — | — | CN | disclosed |
| CN-111491934-A | Amino-fluoropiperidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2020-08-04 | — | — | CN | disclosed |
| EP-3638229-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2019-05-21 | — | — | US | disclosed |
| WO-2018232094-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2017106771-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | LRRK2, PRKDC, DAPK2 | CHUK 479/4885LRRK2 1/4885ROCK2 342/4885 |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | CHUK 39/4885LRRK2 806/4885ROCK2 59/4885 |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | LRRK2, PRKDC, DAPK2 | CHUK 479/4885LRRK2 1/4885ROCK2 342/4885 |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | LRRK2, PRKDC, DAPK2 | CHUK 479/4885LRRK2 1/4885ROCK2 342/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | CHUK 39/4885LRRK2 806/4885ROCK2 59/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | CHUK 39/4885LRRK2 806/4885ROCK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.